DRL Launches Wearable Therapy Device For Migraine Management In India

Dr Reddy's Laboratories Ltd has introduced Nerivio, an innovative wearable therapy device approved by the United States Food and Drug Administration (USFDA), for the drug-free management of migraines in India. This state-of-the-art device offers a non-invasive solution for both acute and preventive treatment of migraines, providing relief to adults and adolescents aged 12 years and above.

Nerivio, a prescription-based device, is designed to be worn on the upper arm and comes with 18 pre-programmed 45-minute treatment sessions. It is recommended for use within 60 minutes of the onset of a headache for acute treatment or every alternate day for migraine prevention.

The device employs Remote Electrical Neuromodulation (REN) to activate conditioned pain modulation by stimulating nerve endings. This stimulation initiates a natural pain-relieving process in the brainstem, resulting in a global effect of pain inhibition that targets the source of migraine pain in the head.

Accompanying the device is the Nerivio app, available for free download on both the Google Play Store and the Apple App Store. The app not only allows users to control the intensity levels of the device but also provides an interactive migraine diary. This feature enables users to log symptoms, track responses, and share insightful analytics. Additionally, the app features a Guided Imagery, Education, and Relaxation (GIER) protocol, which, when used with Nerivio, significantly enhances response rates.

MV Ramana, Chief Executive Officer, Branded Markets (India and Emerging Markets) at Dr Reddy's, expressed enthusiasm about the Nerivio launch, stating, "The roll-out of Nerivio marks our entry into digital therapeutics (DTx). It is an area that is seeing increasing adoption by physicians as well as patients due to its potential to reduce pill burden and decrease dependency on non-specific medication in chronic or hard-to-treat diseases."

Ramana emphasized the significance of Nerivio in addressing the unmet clinical needs of migraine patients, citing its USFDA approval, drug-free nature, noninvasive design, and favourable safety profile. He noted, "Given the migraine disease burden, its associated symptoms, lack of effective treatment and impact on well-being, quality of life and productivity, we are happy to bring Nerivio to India."

While acknowledging the continued growth of their core generics business, Ramana highlighted Nerivio as part of Dr Reddy's broader innovative products initiatives in India, alongside their e-commerce venture 'Celevida Wellness' and recent deals to bring novel molecules like toripalimab and pyrotinib to the country.